OBJECTIVES: To determine the quality of life (QoL) of MS patients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile. BACKGROUND: IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far. METHODS: Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MS patients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects. RESULTS: During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL. CONCLUSIONS: Our findings suggest that IFN-beta therapy has an impact on QoL of MS patients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342
OBJECTIVES: To determine the quality of life (QoL) of MSpatients during the initial 6 months of treatment with interferon-beta (IFN-beta). Furthermore, to determine whether changes in QoL relate to disability, emotional state, therapeutic expectations or side effect profile. BACKGROUND:IFN-beta has been shown to have beneficial effects on the course of MS. Since the aim of IFN-beta treatment is not to cure but to slow down the disease it is important to know how this treatment affects QoL. Surprisingly, the impact of treatment with IFN-beta on QoL measures has not been extensively studied so far. METHODS: Case report documentation, including EDSS, SF-36 and MADRAS scores, of 51 relapsing-remitting MSpatients treated with IFN-beta was obtained at baseline and at months 1, 3 and 6. Patients also filled in a form about their expectations of therapy and a questionnaire on side effects. RESULTS: During treatment there was a significant linear trend indicating improvement in the role-physical functioning (RPF) scale of the SF-36 (F(1,50)=4.9, P=0.032). A transient decrease at month 1 was found in the scale for bodily pain, indicating more experienced pain (F(1,50)=19.8, P<0.001). Subgroup analysis showed that patients with most depressive symptoms on the MADRAS at baseline contributed most to the increase in RPF scores over time (F(1,24)=5,6 P=0.026). Furthermore, we found associations between adverse event scores and several domains of QoL. CONCLUSIONS: Our findings suggest that IFN-beta therapy has an impact on QoL of MSpatients in that it improves role-physical functioning and transiently worsens experienced bodily pain. QoL during treatment with IFN-beta is influenced by depressive symptoms at baseline as well as by treatment-associated side-effects. Multiple Sclerosis (2000) 6 338 - 342
Authors: Peter J Jongen; Dirk Lehnick; Evert Sanders; Pierette Seeldrayers; Sten Fredrikson; Magnus Andersson; Joachim Speck Journal: Health Qual Life Outcomes Date: 2010-11-15 Impact factor: 3.186
Authors: J D Fisk; M G Brown; I S Sketris; L M Metz; T J Murray; K J Stadnyk Journal: J Neurol Neurosurg Psychiatry Date: 2005-01 Impact factor: 10.154
Authors: E M Mowry; A Beheshtian; E Waubant; D S Goodin; B A Cree; P Qualley; R Lincoln; M F George; R Gomez; S L Hauser; D T Okuda; D Pelletier Journal: Neurology Date: 2009-05-19 Impact factor: 9.910
Authors: Isabella Laura Simone; Antonia Ceccarelli; Carla Tortorella; Alessandra Bellacosa; Fabio Pellegrini; Immacolata Plasmati; Maria Fara De Caro; Mariangela Lopez; Francesco Girolamo; Paolo Livrea Journal: Health Qual Life Outcomes Date: 2006-12-12 Impact factor: 3.186
Authors: Gilles Defer; Sophie Fedrizzi; Damien Chevanne; François Montastruc; Anais R Briant; Jean-Jacques Parienti; Laure Peyro-Saint-Paul Journal: Drug Saf Date: 2020-10-13 Impact factor: 5.606